CoChat
Sign Up
Cited by 53Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 226 of the 226 references it cites were found in a registry or an index.

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors

Open access
Roy, Dia, Gilmour, Cassandra, Patnaik, Sachin, Wang, Li Lily·2023·Frontiers in Immunology
DOI 10.3389/fimmu.2023.1264327PMC PMC10620683
Open this paper in CoChat — free accountOpen PDF

Abstract

The differentiation, survival, and effector function of tumor-specific CD8+ cytotoxic T cells lie at the center of antitumor immunity. Due to the lack of proper costimulation and the abundant immunosuppressive mechanisms, tumor-specific T cells show a lack of persistence and exhausted and dysfunctional phenotypes. Multiple coinhibitory receptors, such as PD-1, CTLA-4, VISTA, TIGIT, TIM-3, and LAG-3, contribute to dysfunctional CTLs and failed antitumor immunity. These coinhibitory receptors are collectively called immune checkpoint receptors (ICRs). Immune checkpoint inhibitors (ICIs) targeting these ICRs have become the cornerstone for cancer immunotherapy as they have established new clinical paradigms for an expanding range of previously untreatable cancers. Given the nonredundant yet convergent molecular pathways mediated by various ICRs, combinatorial immunotherapies are being tested to bring synergistic benefits to patients. In this review, we summarize the mechanisms of several emerging ICRs, including VISTA, TIGIT, TIM-3, and LAG-3, and the preclinical and clinical data supporting combinatorial strategies to improve existing ICI therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1264327

Cites

226 of 226 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overview of coinhibitory ICRs and their effects in conventional T cells. T-cell activation requires TCR recognition of cognate antigens presented on APCs and costimulation provided by B7/CD28 or CD115/CD226 interactions. On the other hand, many coinhibitory ligand/receptor pathways are activated to dampen T-cell responses. The B7/CTLA-4 and PD-L1/2/PD-1 pathways are the cornerstones of the immune checkpoint paradigm. Emerging inhibitory ICRs, including TIGIT, LAG-3, TIM-3, and VISTA, each recognized by multiple ligands, play nonredundant yet convergent roles as the “brakes” of T-cell responses.
Figure 1 Overview of coinhibitory ICRs and their effects in conventional T cells. T-cell activation requires TCR recognition of cognate antigens presented on APCs and costimulation provided by B7/CD28 or CD115/CD226 interactions. On the other hand, many coinhibitory ligand/receptor pathways are activated to dampen T-cell responses. The B7/CTLA-4 and PD-L1/2/PD-1 pathways are the cornerstones of the immune checkpoint paradigm. Emerging inhibitory ICRs, including TIGIT, LAG-3, TIM-3, and VISTA, each recognized by multiple ligands, play nonredundant yet convergent roles as the “brakes” of T-cell responses.CC BY · PubMed Central
Figure 2 The signaling effects of ICRs in antigen-presenting cells. Aside from suppressing T-cell activation, many ICRs regulate the maturation, antigen presentation, cytokine production, and other effector functions of DCs and tumor-associated macrophages. CTLA-4 reduces the surface expression of B7 molecules through trans-endocytosis. LAG-3 and TIGIT trigger signaling in a reverse direction by engaging their respective binding partners MHCII and CD155. On the other hand, PD-1, TIM-3, and VISTA are expressed in APCs and transmit inhibitory signals to inhibit the effector functions of APCs, including phagocytosis, antigen presentation, and cytokine production. Both PD-1 and VISTA are also expressed in tumor-driven MDSCs and contribute to the differentiation and suppressive function of MDSCs.
Figure 2 The signaling effects of ICRs in antigen-presenting cells. Aside from suppressing T-cell activation, many ICRs regulate the maturation, antigen presentation, cytokine production, and other effector functions of DCs and tumor-associated macrophages. CTLA-4 reduces the surface expression of B7 molecules through trans-endocytosis. LAG-3 and TIGIT trigger signaling in a reverse direction by engaging their respective binding partners MHCII and CD155. On the other hand, PD-1, TIM-3, and VISTA are expressed in APCs and transmit inhibitory signals to inhibit the effector functions of APCs, including phagocytosis, antigen presentation, and cytokine production. Both PD-1 and VISTA are also expressed in tumor-driven MDSCs and contribute to the differentiation and suppressive function of MDSCs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 226 references

Research works printed but not linked: 1

  1. Huang, 2015, LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model, Oncotarget, 6, 10.18632/oncotarget.4751 · DOI

Cited by

Sorted by citations

See all 53

Related

Metadata

Authors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L.
Affiliations
Cleveland Clinic (US)
Corresponding author
Wang, Li Lily
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2023-10-19
Volume
14
Pages
1264327-1264327
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2023.1264327
PMC
PMC10620683
OpenAlex
W4387777058
Cited by
53
References
226
Citations by year
2026: 15 · 2025: 24 · 2024: 13 · 2023: 1
FWCI
1.71
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Defense (W81XWH)
  • National Cancer Institute (R01CA223804, R21CA258618, R01CA164225, F31CA257276)
  • Congressionally Directed Medical Research Programs (W81XWH-21-MRP-MCAA ME210229, W81XWH-21-LCRP-IITRA LC210336)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
immune checkpoint receptors, immune checkpoint inhibitors, combination immunotherapy, T cell exhaustion, PD-1, CTLA-4, VISTA, TIGIT, TIM-3, LAG-3, cytotoxic T lymphocytes, antitumor immunity, costimulation
MeSH terms
Hepatitis A Virus Cellular Receptor 2, Humans, Immunotherapy, Neoplasms, Receptors, Immunologic, T-Lymphocytes, Cytotoxic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review